Evidence map›Paper›PMID 27698698›Full record

ArticleExperimental and therapeutic medicine2016

Downregulation of microRNA-132 indicates progression in hepatocellular carcinoma.

Xin Zhang, Wei Tang, Ruishan Li, Rongquan He, Tingqing Gan, Yihuan Luo, Gang Chen, Minhua Rong

Abstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xin ZhangResearch Department, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Wei TangDepartment of Breast Surgery, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Ruishan LiResearch Department, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Rongquan HeDepartment of Medical Oncology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Tingqing GanDepartment of Medical Oncology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Yihuan LuoDepartment of Pathology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Gang ChenDepartment of Pathology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Minhua RongResearch Department, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although miR-132 has been studied in various human tumors, few studies have investigated the role of miR-132 in hepatocellular carcinoma (HCC). The present study aimed to evaluate the associations between miR-132 and clinicopathological parameters, including recurrence, in patients with HCC. Reverse transcription-quantitative polymerase chain reaction analysis was used to detect the expression levels of miR-132 in 95 cases of HCC and their corresponding non-cancerous liver tissues. Th e associations between miR-132 expression levels and clinicopathological characteristics, including recurrence, were investigated in patients with HCC. miR-132 expression levels were significantly reduced in HCC tissues, as compared with adjacent non-cancerous tissues (1.9245±0.7564 vs. 2.7326±1.1475; P<0.001). The area under curve (AUC) of receiver operating characteristic (ROC) used to distinguish cancerous and non-cancerous tissues was 0.711 for miR-132 expression (95% confidence interval, 0.637-0.785; P<0.001) and the optimal cut-off value was 2.25. Expression levels of miR-132 were significantly reduced in the distant metastasis (P=0.031), advanced clinical TNM stage (P=0.022), hepatitis B virus-positive (P<0.001), NM23-expressed (P=0.034), high Ki-67 labeling index (LI; P=0.005) and tumor infiltration or no capsule groups (P=0.026). Spearman correlation analysis demonstrated that miR-132 was significantly correlated with hepatitis B virus infection (

Indexed as

hepatocellular carcinomamicroRNA-132progressionreverse transcription-quantitative polymerase chain reaction

Identifiers

PMID27698698
PMCPMC5038555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.